Page last updated: 2024-10-19

niacinamide and Mesothelioma

niacinamide has been researched along with Mesothelioma in 6 studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Mesothelioma: A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)

Research Excerpts

ExcerptRelevanceReference
"Sorafenib is well tolerated in patients with mesothelioma after completion of platinum-containing chemotherapy."9.17Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy. ( Barrington, S; Cane, P; Dunn, JT; Lal, R; Landau, D; Lang-Lazdunski, L; McLennan, B; Papa, S; Popat, S; Prevost, AT; Shah, R; Spicer, J; Viney, Z, 2013)
"We analyzed the molecular mechanisms of the antiproliferative effects of sorafenib in mesothelioma TIC cultures."7.85The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells. ( Barbieri, F; Carra, E; Daga, A; Favoni, RE; Filiberti, RA; Florio, T; Marubbi, D; Mutti, L; Pattarozzi, A; Würth, R, 2017)
"Sorafenib is a potent inhibitor of the ras/raf/MEK pathway and also targets VEGFR and cKIT."6.75A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. ( Crawford, J; Dubey, S; Heinze, R; Jänne, PA; Kindler, HL; Kratzke, R; Krug, L; Pang, H; Vokes, E; Wang, X; Watt, C, 2010)
"Sorafenib is well tolerated in patients with mesothelioma after completion of platinum-containing chemotherapy."5.17Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy. ( Barrington, S; Cane, P; Dunn, JT; Lal, R; Landau, D; Lang-Lazdunski, L; McLennan, B; Papa, S; Popat, S; Prevost, AT; Shah, R; Spicer, J; Viney, Z, 2013)
"We analyzed the molecular mechanisms of the antiproliferative effects of sorafenib in mesothelioma TIC cultures."3.85The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells. ( Barbieri, F; Carra, E; Daga, A; Favoni, RE; Filiberti, RA; Florio, T; Marubbi, D; Mutti, L; Pattarozzi, A; Würth, R, 2017)
"Sorafenib is a potent inhibitor of the ras/raf/MEK pathway and also targets VEGFR and cKIT."2.75A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. ( Crawford, J; Dubey, S; Heinze, R; Jänne, PA; Kindler, HL; Kratzke, R; Krug, L; Pang, H; Vokes, E; Wang, X; Watt, C, 2010)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Pattarozzi, A1
Carra, E1
Favoni, RE1
Würth, R1
Marubbi, D1
Filiberti, RA1
Mutti, L1
Florio, T1
Barbieri, F1
Daga, A1
Papa, S1
Popat, S1
Shah, R1
Prevost, AT1
Lal, R1
McLennan, B1
Cane, P1
Lang-Lazdunski, L1
Viney, Z1
Dunn, JT1
Barrington, S1
Landau, D1
Spicer, J1
Pignochino, Y1
Dell'Aglio, C1
Inghilleri, S1
Zorzetto, M1
Basiricò, M1
Capozzi, F1
Canta, M1
Piloni, D1
Cemmi, F1
Sangiolo, D1
Gammaitoni, L1
Soster, M1
Marchiò, S1
Pozzi, E1
Morbini, P1
Luisetti, M1
Aglietta, M1
Grignani, G1
Stella, GM1
Katz, SI1
Zhou, L1
Chao, G1
Smith, CD1
Ferrara, T1
Wang, W1
Dicker, DT1
El-Deiry, WS1
Dubey, S1
Jänne, PA1
Krug, L1
Pang, H1
Wang, X1
Heinze, R1
Watt, C1
Crawford, J1
Kratzke, R1
Vokes, E1
Kindler, HL1
Schouwink, H1
Ruevekamp, M1
Oppelaar, H1
van Veen, R1
Baas, P1
Stewart, FA1

Trials

2 trials available for niacinamide and Mesothelioma

ArticleYear
Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013, Volume: 8, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm;

2013
A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:10

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Extracellular Signal-Regulated MAP Kinases; Female;

2010

Other Studies

4 other studies available for niacinamide and Mesothelioma

ArticleYear
The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
    Stem cell research & therapy, 2017, 05-25, Volume: 8, Issue:1

    Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Separation; C

2017
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.
    BMC cancer, 2015, May-08, Volume: 15

    Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cyt

2015
Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.
    Cancer biology & therapy, 2009, Volume: 8, Issue:24

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Caspase 3; Cell Line, Tumor; Extracell

2009
Photodynamic therapy for malignant mesothelioma: preclinical studies for optimization of treatment protocols.
    Photochemistry and photobiology, 2001, Volume: 73, Issue:4

    Topics: Animals; Carbon Dioxide; Combined Modality Therapy; Disease Models, Animal; Dose-Response Relationsh

2001